ClinicalTrials.gg
RecruitingNCT05633888Updated Mar 20, 2024

Post-Market Feasibility Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System

An interventional study of CATAMARAN SI Joint Fusion System in Sacroiliac Joint Disruption and Degenerative Sacroiliitis, sponsored by Tenon Medical. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Tenon Medical · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 3 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the outcomes of patients with sacroiliac joint pain treated with the CATAMARAN SI Joint Fusion System.

Read the detailed description

This is a multi-center post-market study to evaluate the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the CATAMARAN SI Joint Fusion System.

02

Conditions studied

  • Sacroiliac Joint Disruption
  • Degenerative Sacroiliitis

Browse trials for

03

In context

Sacroiliitis

42 studies on the registry are indexed under Sacroiliitis; 11 are open to participants now.

This study's planned enrollment of 50 is close to the median of 48 across 28 interventional studies indexed under Sacroiliitis.

Browse Sacroiliitis studies →

Lead sponsor

Tenon Medical is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following:

    • Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and
    • Patient has at least 3 of 5 physical examination maneuvers specific for SI joint pain (Fabers, Compression, Distraction,Thigh thrust, Gaenslen's test, and/or Sacral thrust test), and
    • Patient has improvement in lower back pain VAS of at least 50% of the pre injection VAS after fluoroscopic controlled injection of local anesthetic into affected SI joint(s) (including previous documented test \<6 months ago)
  • Patient has failed conservative care (non-surgical) > 6 months
  • Patient has a pre-operative Oswestry Disability Index score > 30%
  • Patient has a pre-operative SI joint pain score of > 50 on a 0-100 mm visual analog scale (VAS)
  • Patient, or authorized representative, signs a written form to participate in the study
  • Patient is willing and able to complete study follow-up requirements

Exclusion criteria

Exclusion Criteria:

  • Planned bi-lateral SI joint fixation
  • Severe lower back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture (this is done by physical exam, medical history, and MRI/CT/X-ray as required)
  • Other known sacroiliac pathology such as: sacral dysplasia, inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA- associated spondyloarthropathy), tumor, acute fracture, crystal arthropathy
  • History of recent (\<1 year) fracture of the pelvis with documented malunion, non-union of sacrum or ilium or any type of internal fixation of the pelvic ring
  • Severe osteoporosis
  • Paget's disease, osteomalacia, osteomalacia or other metabolic bone disease
  • Any condition or anatomy that makes treatment with the CATAMARAN SI Joint Fusion System infeasible including deformity
  • Known allergy to titanium or titanium alloys
  • Morbid obesity
  • Active : a history of any invasive malignancy (except non-melanoma skin cancer), unless the subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least five years
  • Patient has systemic infection or active infection at the treatment site
  • Chronic rheumatologic condition (e.g., rheumatoid arthritis)
  • Patient has uncontrolled diabetes
  • Patient is currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation
  • Prominent neurologic condition that would interfere with physical therapy
  • Patient is pregnant or wishes to become pregnant in the next two years
  • Patient is not likely to comply with the follow-up evaluation schedule
  • Patient is participating in a clinical trial of another drug or device in which the primary endpoint has not occurred
  • Patient has a psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
  • Known or suspected drug or alcohol abuse
  • Patient is a prisoner or a ward of the state
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    CATAMARAN SI Joint Fusion System

    Placement of the Catamaran Fixation Device

    Device: CATAMARAN SI Joint Fusion System

Interventions

  • DeviceCATAMARAN SI Joint Fusion System

    Placement of the Catamaran Fixation Device

06

What researchers measure

Primary outcomes

  1. Proportion of subjects that meet the definition of Subject Success at 6 months post-procedure

    Change from baseline in VAS SI joint pain score to be reduced by at least 20 mm, Lack of device-related serious adverse events, Absence of neurologic worsening related to the sacral spine compared to baseline (unless attributable to a concurrent medical condition or other cause unrelated to the device and/ or study procedure), and Absence of surgical re-intervention (removal, revision, reoperation, or supplemental fixation) for SI joint pain.

    Time frame: 6 months post procedure

07

Study locations

6 of 6 sites recruiting
  • Northwest Specialty Hospital
    Coeur d'Alene, Idaho 83815, United States
    Recruiting
  • Comprehensive Pain and Spine Specialists
    Muncie, Indiana 47304, United States
    Recruiting
  • Vitality Pain Centers
    Louisville, Kentucky 40241, United States
    Recruiting
  • Orthopedic Associates of Duluth
    Duluth, Minnesota 55805, United States
    Recruiting
    • Athena Davies · Contactadavies@twu.edu
    • Mathew Davies, MD · Principal investigator
  • St. Louis Pain Consultants
    Chesterfield, Missouri 63017, United States
    Recruiting
  • St. George Orthopedic Spine
    Saint George, Utah 84790, United States
    Recruiting
    • Mark Stouffer, MD, FAAOS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05633888
Lead sponsor
Tenon Medical
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Nov 14, 2022
Primary completion
Jan 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Mar 20, 2024

Study contacts

Calvin Lincé
Contact
clince@linceconsulting.com
(510)274-7483

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion